Skip to main content
JNJ
NYSE Life Sciences

强生公司的Imaavy获得FDA优先审查用于治疗罕见血液疾病

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
7
Price
$227.11
Mkt Cap
$547.642B
52W Low
$146.115
52W High
$251.71
Market data snapshot near publication time

summarizeSummary

强生公司的药物Imaavy (nipocalimab)已被授予FDA优先审查，用于治疗温性自身免疫性溶血性贫血，一种罕见的血液疾病。这一加速审查状态是在其2/3期Energy研究获得积极结果之后，并表明FDA认可了该药物可能为严重疾病提供重大改进的潜力。这一发展是强生公司药物管线的一个重大积极因素，特别是Imaavy可能成为该特定罕见疾病的首个批准治疗方法，从而加强公司的创新药物板块。投资者现在将关注FDA审查的结果以及nipocalimab在其其他适应症方面的进一步进展。

在该公告发布时，JNJ的交易价格为$227.11，交易所为NYSE，所属行业为Life Sciences，市值约为$5476.4亿。 52周交易区间为$146.12至$251.71。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed JNJ - Latest Insights

JNJ
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Imaavy Secures FDA Priority Review for Rare Blood Disorder
Sentiment: Positive
View Wiseek Article
JNJ
Apr 24, 2026, 9:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J Acquires Atraverse Medical to Bolster Cardiac Device Portfolio
Sentiment: Positive
View Wiseek Article
JNJ
Apr 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
J&J Reports Strong Q1 Operational Sales Growth, Raises Dividend Amidst Talc Litigation Challenges and Increased Net Debt
Sentiment: Neutral
View Wiseek Article
JNJ
Apr 22, 2026, 10:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Nipocalimab-aahu Phase 3 Study Shows Sustained Improvements for Autoantibody Disease
Sentiment: Positive
View Wiseek Article
JNJ
Apr 17, 2026, 6:47 PM EDT
Source: Reuters
Importance Score:
8
Judge Rejects Bayer's Bid to Block J&J's Multibillion-Dollar Prostate Cancer Drug Claims
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
Sentiment: Negative
View Wiseek Article
JNJ
Apr 14, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year
Sentiment: Positive
View Wiseek Article
JNJ
Apr 14, 2026, 6:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
J&J's Innovative Medicine Sales Growth Fueled by Darzalex, Carvykti, Erleada, Rybrevant, Tremfya, and Spravato
Sentiment: Positive
View Wiseek Article
JNJ
Apr 13, 2026, 12:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Johnson & Johnson Q1 Sales Expected Up, Profit Down Ahead of Earnings Report
Sentiment: Neutral
View Wiseek Article
JNJ
Mar 30, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
J&J Secures $500M R&D Pact for JNJ-4804, Reports 71% ORR for JNJ-1900 in NSCLC Trial
Sentiment: Positive
View Wiseek Article